Business
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer
About this update from Medicus Pharma Ltd.
[{"type":"text","content":"200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer\nPHILADELPHIA, March 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\" or the \"Company\"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced it will host a business update conference call at 11:30 a.m. Eastern Time. The call will highlight new analysis from its Phase 2 SkinJect® study, including an overall response rate (ORR) of 80% in the 200µg cohort at Day 57, and outline the Company’s planning toward an agentic AI–enabled clinical development platform. The Company believes these results position the 200µg cohort as the leading dose regimen in the study, demonstrating the highest activity observed to date with continued improvement through Day 57. Conference Call Details Time: 11:30 a.m. ETPre-registration: https://dpregister.com/sreg/10207261/10379bd1029 Dial-in. (US/Canada): 833-890-6070Dial-in. (International): 412-504-9736Q&A Web Link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=DeCGoBHR The Key Highlights to be presented at the conference call are: Independent Clinical Perspective — Dr. Babar Rao (Principal Investigator) The call will feature Dr. Babar Rao, an internationally acclaimed dermatology key opinion leader and Principal Investigator of the SKNJCT-003 study, who will provide an independent clinical interpretation of the dataset. Dr. Rao is a board-certified dermatologist and dermatopathologist, and currently serves as: Professor of Dermatology and Pathology, Rutgers Robert Wood Johnson Medical SchoolClinical Associate Professor of Dermatology, Weill Cornell Medical College He has authored over 200 peer-reviewed publications and has served as principal investigator in multiple dermatology clinical trials. Dr. Rao is expected to highlight: The clinical significance of 73% clearance at Day 57 in the 200µg cohortA clear separation versus device-only active control, supporting incremental drug effectThe role of: Microneedle-mediated tumor disruptionLocal immune activation and wound-healing pathways Importantly, Dr. Rao is expected to place these findings in the context of the broader basal cell carcinoma (B...